Smallpox, a biowarfare weapon;La variole, agent du bioterrorisme

Presse Medicale

Volumn 31, Issue 38, 2002, Pages 1813-1817

  Bossi, Philippe ^a   Bricaire, François ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL WARFARE; ELECTRON MICROSCOPY; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; INFECTION RISK; POLYMERASE CHAIN REACTION; POPULATION EXPOSURE; REVIEW; SMALLPOX; STRAIN DIFFERENCE; VACCINATION; VIRUS STRAIN;

BIOTERRORISM; DISASTER PLANNING; DNA, VIRAL; EUROPE; HEALTH PERSONNEL; HUMANS; MORTALITY; POLYMERASE CHAIN REACTION; PROGNOSIS; PUBLIC HEALTH; SEVERITY OF ILLNESS INDEX; SMALLPOX; SMALLPOX VACCINE; UNITED STATES;

EID: 0037202668     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Arita L. Virological evidence for the success of the smallpox eradication programme. Nature 1979; 279: 293-8.
2. Report of the Investigation into the Cause of the 1978 Birmingham Smallpox Occurrence. London, England: Her Majesty's Stationery Office, 1980.
3. Breman J, Henderson D. Diagnosis and management of smallpox. N Engl J Med 2002; 346: 1300-8.
4. Henderson D, Inglesby T, Bartlett J et al. Smallpox as a biological weapon. Consensus statement. JAMA 1999; 281: 2127-37.
5. Guide Pour l'Investigation Épidémiologique. Variole. InVS, http://www.invs.sante.fr
6. http://www.afssaps.sante.fr/
7. http://www.who.int/emc/diseases/smallpox/Smallpoxeradication.html
8. http://www.phls.org.uk/topics_az/deliberate_releases/menu.htm
9. Biological Threats: A Health Response for Ireland. Comments@health.irlgov.ie
10. Franz D, Jahrling P, Friedlander A et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997; 278: 399-411
11. Fenner F, Henderson D, Arita I, Jezek Z, Ladnyi I. Potential sources for a return of smallpox. In: Smallpox and Its Eradication. Geneva, Switzerland: World Health Organization, 1988: chapter 30: 1341.
12. Jezek Z, Fenner F. Human monkeypox. Virol Monogr 1988; 17: 93-5.
13. Downie A, Meiklejohn M, St Vincent L, Rao A, Sundara Babu B, Kempe C. The recovery of smallpox from patients and their environment in a smallpox hospital. Bull WHO 1965; 33: 615-22.
14. Wolf H, Croon J. Survival of smallpox virus (variola minor) in natural circumstances. Bull WHO 1968; 38: 492-3.
15. McGovern T, Christopher G, Eitzen E. Cutaneous manifestations of biological warfare and related threat agents. Arch Dermatol 1999; 135: 311-22.
16. Baxby D. Human poxvirus infection after eradication of smallpox. Epidemiol Infect 1998; 100: 321-34.
17. The European Agency for the Evaluation of Medicinal Products (CPMP). Guidance Document on Use of Medicinal Products for Treatment and Prophylaxis of Biological Agents that Might be used as Weapons of Bioterrorism. 31 July 2002, Revision 3. http://www.emea.eu.int
18. Bray M, Martinez M, Kefauver D, West M, Roy C. Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir. Antiviral Res 2002; 54: 129-42.
19. Frey S, Couch R, Tacket C et al. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 2002; 346: 1265-74.
20. Frey S, Newman F, Cruz J et al. Dose-related effects of smallpox vaccine. N Engl J Med 2002; 346: 1275-80.
21. Bicknell W. The case for voluntary smallpox vaccination. N Engl J Med 2002; 346: 1323-5.
22. Lévy-Bruhl D, Guérin N. Utilisation du virus de la variole comme arme biologique: Place de la vaccination en France. Eurosurveillance 2001; 6: 171-8.